Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial

This publication has 18 references indexed in Scilit:

• Current evidence for the use of paediatric antiretroviral therapy – a PENTA analysis
  European Journal of Pediatrics, 2000
• Treatment of Human Immunodeficiency Virus 1‐Infected Infants and Children with the Protease Inhibitor Nelfinavir Mesylate
  Clinical Infectious Diseases, 1999
• A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection
  Pediatrics, 1999
• Safety and Single-Dose Pharmacokinetics of Abacavir (1592U89) in Human Immunodeficiency Virus Type 1-Infected Children
  Antimicrobial Agents and Chemotherapy, 1999
• The M184 V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors
  AIDS, 1998
• Antiretroviral Therapy for HIV Infection in 1997
  JAMA, 1997
• British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
  The Lancet, 1997
• Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
  Antimicrobial Agents and Chemotherapy, 1997
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
  British Journal of Cancer, 1977
• Regression Analysis when the Dependent Variable Is Truncated Normal
  Econometrica, 1973